Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Emotion regulation distinguishes unipolar and bipolar depression

Patients with bipolar disorder regulate their emotions differently from those with major depressive disorder in both depressed and remitted states, a study shows.

21 May 2015

Magstim Announces FDA (510k) Clearance of rTMS (repetitive Transcranial Magnetic Stimulation) Therapy System

Magstim is the pioneer of TMS technology, having built a reputation for developing leading medical devices in the research field for over 25 years. ..

From Magstim 21 May 2015

Magstim Rapid2 Therapy System receives FDA clearance for treatment of drug resistant MDD

The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, has received FDA 510(k) clearance to market its Magstim Rapid2 Therapy System for the treatment of drug resistant Major Depressive Disorder (MDD) in the United States. The clearance enables Magstim to significantly increase access to cutting-edge Repetitive Transcranial Magnetic Stimulation (rTMS) technology for patients and clinicians.

From Magstim 20 May 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.

8 May 2015

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI Methylation Sciences, Inc., a pharmaceutical company developing a once-daily oral, small molecule therapy for adjunctive treatment of major depressive disorder (MDD), announced the completion of patient recruitment for its HORIZON Phase 2 Study.

7 May 2015

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

A multidisciplinary team of Johns Hopkins researchers has developed two new strategies to treat depression in young people using the selective serotonin reuptake inhibitor (SSRI) class of medications. These strategies, published May 5 in the journal Translational Psychiatry, incorporate a new understanding of how to mitigate the risk of suicide while on SSRI treatment.

6 May 2015

Clinical features identified to distinguish bipolar I disorder from MDD

Researchers have identified seven clinical features that could help distinguish patients with bipolar disorder from those with major depressive disorder.

29 Apr 2015

Neuronetics completes Series F Financing Round

Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million.

27 Apr 2015

Tal Medical raises $14 million funding round from new and existing investors

Tal Medical, a clinical-stage medical device company developing a new treatment for depression and other psychiatric disorders, today announced a $14 million funding round from existing investor PureTech, a new institutional investor, and several prominent individual investors.

21 Apr 2015

Roseroot extract may be beneficial for treating major depressive disorder

Rhodiola rosea (R. rosea), or roseroot, may be a beneficial treatment option for major depressive disorder (MDD), according to results of a study in the journal Phytomedicine led by Jun J. Mao, MD, MSCE, associate professor of Family Medicine, Community Health and Epidemiology and colleagues at the Perelman School of Medicine of University of Pennsylvania.

27 Mar 2015

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Research results published in the Journal of Neurotrauma and conducted by the Walter Reed Army Institute of Research (WRAIR) as part of a collaboration with Concert Pharmaceuticals, Inc. showed that a novel deuterium-containing sigma-1 agonist invented at Concert, called C-10068, demonstrated anti-seizure and anti-inflammatory effects in a preclinical model of traumatic brain injury (TBI).

24 Mar 2015

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem, Inc. announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated.

12 Mar 2015

Study finding suggests importance of individually-tailored treatment for depression

The most commonly used treatment for the over 14 million Americans who suffer from Major Depressive Disorder is anti-depressant medication. While such medications bring relief to many, current research suggests that one size may not fit all when it comes to treating depression.

12 Mar 2015

Study: Family Based Interpersonal Psychotherapy effective in treating preadolescents with depression

A recent study published in the March 2015 issue of the Journal of the American Academy of Child and Adolescent Psychiatry finds that Family Based Interpersonal Psychotherapy (FB-IPT) is more effective in treating preadolescent children with depression compared to child-centered therapy (CCT).

4 Mar 2015

Pain from social rejection lasts longer for people with untreated depression

Rejected by a person you like? Just "shake it off" and move on, as music star Taylor Swift says.

27 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

Major Depressive Disorder News and Research

Further Reading

Emotion regulation distinguishes unipolar and bipolar depression

Magstim Announces FDA (510k) Clearance of rTMS (repetitive Transcranial Magnetic Stimulation) Therapy System

Magstim Rapid2 Therapy System receives FDA clearance for treatment of drug resistant MDD

Orexigen Therapeutics provides update on business and financial results for Q1 2015

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

Clinical features identified to distinguish bipolar I disorder from MDD

Neuronetics completes Series F Financing Round

Tal Medical raises $14 million funding round from new and existing investors

Roseroot extract may be beneficial for treating major depressive disorder

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Study finding suggests importance of individually-tailored treatment for depression

Study: Family Based Interpersonal Psychotherapy effective in treating preadolescents with depression

Pain from social rejection lasts longer for people with untreated depression

Actavis provides overview of standalone global pharmaceutical development pipeline

Brain scans can predict therapeutic responses to talk therapy

Chronic pain common in affective disorders

Majority of Canada's homeless adults with mental illness show evidence of cognitive deficits

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News